Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Discovery
Cancer Discovery

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases

More articles from Research Watch

  • The EZH2 Inhibitor Tazemetostat Is Well Tolerated in a Phase I Trial
    Cancer Discovery Apr 2018, DOI: 10.1158/2159-8290.CD-RW2018-067
  • Dual Targeting of MDMX and MDM2 Has Antileukemic Activity
    Cancer Discovery Apr 2018, DOI: 10.1158/2159-8290.CD-RW2018-068
  • A Cancer-Germline Antigen Signature Predicts Anti-CTLA4 Resistance
    Cancer Discovery Apr 2018, DOI: 10.1158/2159-8290.CD-RW2018-066
  • Loss of p62 in Adipocytes Promotes Aggressive Prostate Cancer
    Cancer Discovery Apr 2018, DOI: 10.1158/2159-8290.CD-RW2018-069
  • Glioblastoma Stem Cell–Tumor Cell Cross-talk Drives Gliomagenesis
    Cancer Discovery Apr 2018, DOI: 10.1158/2159-8290.CD-RW2018-062
  • Larotrectinib Has Antitumor Activity in TRK+ Pediatric Solid Tumors
    Cancer Discovery Apr 2018, DOI: 10.1158/2159-8290.CD-RW2018-063
  • SLAM-seq Identifies Direct Transcriptional Targets of BRD4 and MYC
    Cancer Discovery Apr 2018, DOI: 10.1158/2159-8290.CD-RW2018-064
  • The IL15 Superagonist ALT-803 plus Nivolumab Has Antitumor Activity
    Cancer Discovery Apr 2018, DOI: 10.1158/2159-8290.CD-RW2018-065
  • Ibrutinib plus Venetoclax May Be Effective in Mantle-Cell Lymphoma
    Cancer Discovery Apr 2018, DOI: 10.1158/2159-8290.CD-RW2018-060
  • Trastuzumab Extends Progression-Free Survival in HER2/neu+ Uterine Tumors
    Cancer Discovery Apr 2018, DOI: 10.1158/2159-8290.CD-RW2018-059

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 162
  • Home
  • Alerts
  • Feedback
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement